The avidities of anti-tau antibodies were significantly higher in the CSF in comparison with those in the serum in both the MS group and the control group (MS group: CSF vs. serum p<0.0001; controls: CSF vs. serum p<0.005). The gene discussed is MAPT; the disease is myeloid sarcoma.